(Q37642783)

21 August 2017

1 reference

title

Organ-sparing strategies in the management of invasive bladder cancer (English)

1 reference

21 August 2017

3

Wassim Kassouf

1 reference

21 August 2017

1

Faysal A Yafi

1 reference

21 August 2017

Fabio L Cury

2

1 reference

21 August 2017

publication date

1 December 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1765-1775

1 reference

21 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Bladder preservation: optimizing radiotherapy and integrated treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Organ preservation for muscle-invasive bladder cancer by transurethral resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

The place of radiation therapy as definitive treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Bladder cancer.Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Molecular targets and targeted therapies in bladder cancer management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Urothelial dysplasia concomitant with bladder tumours: a determinant for future new occurrences in patients treated by full-course radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Radiotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Complications and results after cystectomy in male and female patients with locally invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Salvage cystectomy after radical irradiation for bladder cancer-prognostic factors and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Distressful symptoms after radical radiotherapy for urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.151

21 January 2018

Identifiers

DOI

10.1586/ERA.09.151

1 reference

21 August 2017

1 reference